Author

Y. Stienstra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Organism:human· 1 Assay:metagenomics· 1 Assay:proteomics· 1

Frequent Co-Authors

T. F. Omansen· 2 shared T. S. van der Werf· 2 shared B. M. ter Ellen· 1 shared B. Troost· 1 shared B. Y. Chua· 1 shared D. Almeida· 1 shared D. C. Jackson· 1 shared D. P. I. van de Pol· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

T. F. Omansen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells

N. Dinesh Kumar, B. M. ter Ellen, E. M. Bouma, B. Troost, D. P. I. van de Pol, H. H. van der Ende-Metselaar, D. van Gosliga, L. Apperloo, O. A. Carpaij, M. van den Berge, M. C. Nawijn, Y. Stienstra, I. A. Rodenhuis-Zybert, J. Smit

This study compares the antiviral activity of moxidectin and ivermectin against SARS-CoV-2 in Vero E6 cells and human airway epithelial cells, finding inhibition in Vero cells but not in human cells.

bioRxiv · May 17, 2021Microbiology

Bioluminscent Mycobacterium ulcerans, a tool to study host-pathogen interactions in a murine tail model of Buruli ulcer

T. F. Omansen, R. A. Marcsisin, B. Y. Chua, W. Zeng, D. C. Jackson, J. L. Porter, Y. Stienstra, T. S. van der Werf, T. P. Stinear

This study uses bioluminescent Mycobacterium ulcerans in a mouse tail model to monitor Buruli ulcer progression and evaluate immune responses.

bioRxiv · Oct 3, 2018 · PreprintMicrobiology

High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease

T. F. Omansen, D. Almeida, P. J. Converse, S.-Y. Li, J. Lee, Y. Stienstra, T. S. van der Werf, J. H. Grosset, E. Nuermberger

This study evaluates higher doses of rifamycins in a mouse model of Buruli ulcer, finding dose-dependent efficacy and potential for shorter treatment regimens.

bioRxiv · Aug 19, 2018Microbiology